ArticleJournal of the American Heart Association2022
Cost-of-Illness Analysis of Long-Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Artificial intelligence in computational modeling of thrombosis: Bridging mechanistic insights and clinical translation.Journal of thrombosis and thrombolysis · 2026Pooled it
- Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial.Journal of the American Heart Association · 2025Trial
- Cost-effectiveness of modified diagnostic strategy to safely rule-out pulmonary embolism in the emergency department: a non-inferiority cluster crossover randomized trial (MODIGLIA-NI).BMC emergency medicine · 2023Trial
- Temporal trends in hospital-recorded pulmonary embolism in England before, during and after the COVID-19 pandemic (2008-2024): a population-based observational study.The Lancet regional health. Europe · 2025Article
- Development and validation of a prediction model for venous thromboembolic events following hematoma evacuation in patients with spontaneous intracerebral hemorrhage.Neurosurgical review · 2025Article
- Drivers and recent trends of hospitalisation costs related to acute pulmonary embolism.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Socioeconomic Burden of Pulmonary Embolism in Europe: Shifting Priorities and Challenges for Novel Reperfusion Strategies.Thrombosis and haemostasis · 2025Review
- Hospital Costs of Intracranial Haemorrhage in Patients with Acute Pulmonary Embolism: Possible Implications for Emerging Therapies.Thrombosis and haemostasis · 2025Article
- Estimated annual healthcare costs after acute pulmonary embolism: results from a prospective multicentre cohort study.European heart journal. Quality of care & clinical outcomes · 2025Article
- Rethinking Pulmonary Embolism Management with an Interventional Perspective.Journal of clinical medicine · 2025Review
- Development and Validation of a Predictive Nomogram for Venous Thromboembolism Risk in Multiple Myeloma Patients: A Single-Center Cohort Study in China.Biomedicines · 2025Article
- Healthcare resource utilisation and associated costs after low-risk pulmonary embolism: pre-specified analysis of the Home Treatment of Pulmonary Embolism (HoT-PE) study.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism.Research and practice in thrombosis and haemostasis · 2025Article
- Cost-effective screening strategy to prevent venous thromboembolism in combined oral contraceptive users.Frontiers in endocrinology · 2025Article
- Novel Challenges and Therapeutic Options for Pulmonary Embolism and Deep Vein Thrombosis.Journal of personalized medicine · 2024Review
- Pulmonary perfusion defects or residual vascular obstruction and persistent symptoms after pulmonary embolism: a systematic review and meta-analysis.ERJ open research · 2024Article
- Percutaneous interventions for pulmonary embolism.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Review
- Cardiopulmonary exercise testing during follow-up after acute pulmonary embolism.The European respiratory journal · 2023Article
- Abelacimab for Acute Pulmonary Embolism: Translating Dual FXI/XIa Inhibition from Mechanism to Clinical Prospects.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background As mortality from pulmonary embolism (PE) decreases, the personal and societal costs among survivors are receiving increasing attention. Detailing this burden would support an efficient public health resource allocation. We aimed to provide estimates for the economic and disease burden of PE also accounting for long-term health care use and both direct and indirect costs beyond the acute phase. Methods and Results This is a cost-of-illness analysis with a bottom-up approach based on data from the PREFER in VTE registry (Prevention of Thromboembolic Events-European Registry in Venous Thromboembolism). We calculated direct (clinical events and anticoagulation) and indirect costs (loss of productivity) of an acute PE event and its 12-month follow-up in 2020 Euros. We estimated a disability weight for the 12-month post-PE status and corresponding disability adjusted life years presumably owing to PE. Disease-specific costs in the first year of follow-up after an incident PE case ranged between 9135 Euros and 10 620 Euros. The proportion of indirect costs was 42% to 49% of total costs. Costs were lowest in patients with ongoing cancer, mainly because productivity loss was less evident in this already burdened population. The calculated disability weight for survivors who were cancer free 12 months post-PE was 0.017, and the estimated disability adjusted life years per incident case were 1.17. Conclusions The economic burden imposed by PE to society and affected patients is considerable, and productivity loss is its main driver. The disease burden from PE is remarkable and translates to the loss of roughly 1.2 years of healthy life per incident PE case.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.